JP2026021336A - Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法 - Google Patents

Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法

Info

Publication number
JP2026021336A
JP2026021336A JP2025169285A JP2025169285A JP2026021336A JP 2026021336 A JP2026021336 A JP 2026021336A JP 2025169285 A JP2025169285 A JP 2025169285A JP 2025169285 A JP2025169285 A JP 2025169285A JP 2026021336 A JP2026021336 A JP 2026021336A
Authority
JP
Japan
Prior art keywords
binding agent
amino acid
seq
acid sequence
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025169285A
Other languages
English (en)
Japanese (ja)
Inventor
ジェニファー トンラン ウー，
Original Assignee
キャンキュア， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2022578860A external-priority patent/JP7854948B2/ja
Application filed by キャンキュア， エルエルシー filed Critical キャンキュア， エルエルシー
Publication of JP2026021336A publication Critical patent/JP2026021336A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
JP2025169285A 2020-07-07 2025-10-07 Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法 Pending JP2026021336A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063049012P 2020-07-07 2020-07-07
US63/049,012 2020-07-07
JP2022578860A JP7854948B2 (ja) 2020-07-07 2021-07-06 Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法
PCT/US2021/040445 WO2022010847A1 (en) 2020-07-07 2021-07-06 Mic antibodies and binding agents and methods of using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022578860A Division JP7854948B2 (ja) 2020-07-07 2021-07-06 Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法

Publications (1)

Publication Number Publication Date
JP2026021336A true JP2026021336A (ja) 2026-02-10

Family

ID=77127088

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025169285A Pending JP2026021336A (ja) 2020-07-07 2025-10-07 Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法

Country Status (9)

Country Link
US (2) US12139539B2 (https=)
EP (1) EP4178678A1 (https=)
JP (1) JP2026021336A (https=)
KR (2) KR20230152783A (https=)
CN (1) CN116249716A (https=)
AU (1) AU2021305084A1 (https=)
CA (1) CA3184940A1 (https=)
TW (1) TW202216776A (https=)
WO (1) WO2022010847A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250230246A1 (en) * 2021-10-27 2025-07-17 Samyang Biopharm Usa Inc. Anti-mic antibodies with variant fc domains
WO2023225626A2 (en) * 2022-05-20 2023-11-23 Adanate, Inc. Multi-targeting lilrb antibodies and uses thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
WO1999063050A2 (en) 1998-06-02 1999-12-09 Dendreon Corporation Method for preparation and in vivo administration of antigen presenting cell composition
US20030167531A1 (en) 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
US6512162B2 (en) 1998-07-10 2003-01-28 Calgene Llc Expression of eukaryotic peptides in plant plastids
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
BR0014945A (pt) 1999-10-21 2004-08-31 Monsanto Co Modificação pós-traducional de proteìnas recombinantes produzidas em plantas
AU1811801A (en) 1999-12-03 2001-06-12 Dendreon Corporation Cryopreservation of antigen-loaded dendritic cells and their precursors in serum-free media
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
ATE507295T1 (de) 2000-03-30 2011-05-15 Dendreon Corp Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US20080196111A1 (en) 2005-03-18 2008-08-14 Innate Pharma S.A. Expression Vectors and Methods for Obtaining Nk Cell Specific Expression
EP2083857A4 (en) 2006-09-22 2010-03-24 Dana Farber Cancer Res Inc METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
US10865233B2 (en) 2008-12-18 2020-12-15 Dana-Farber Cancer Institute, Inc. NKG2D-fc for immunotherapy
WO2012091756A1 (en) 2010-12-30 2012-07-05 Avidbiotics Corp. Non-natural mic proteins
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
HUE034044T2 (en) 2011-09-30 2018-01-29 Dana Farber Cancer Inst Inc Therapeutic peptides
AU2013218017B2 (en) 2012-02-07 2017-12-07 Innate Pharma MICA binding agents
JP6647868B2 (ja) 2013-02-20 2020-02-14 ノバルティス アーゲー ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置
SG11201506766PA (en) 2013-03-15 2015-09-29 Dana Farber Cancer Inst Inc Therapeutic peptides
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2015003114A1 (en) * 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
CA2946312A1 (en) 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
AU2015264114A1 (en) 2014-05-21 2016-11-03 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti BiP or anti MICA antibodies
MX2017002205A (es) 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
MX392487B (es) 2014-10-20 2025-03-21 Juno Therapeutics Inc Métodos y composiciones para dosificación en terapia celular adoptiva.
ES2818103T3 (es) 2015-01-16 2021-04-09 Juno Therapeutics Inc Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
EP3288569A4 (en) 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3307876B1 (en) 2015-06-10 2023-09-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
EP3383426A1 (en) 2015-12-04 2018-10-10 Dana Farber Cancer Institute, Inc. Vaccination with mica/b alpha 3 domain for the treatment of cancer
KR20180123214A (ko) 2015-12-09 2018-11-15 난트 홀딩스 아이피, 엘엘씨 Her2 양성 전이성 유방암의 치료를 위한 조성물 및 방법
CA3040421A1 (en) 2016-10-19 2018-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
US10801013B2 (en) 2017-03-08 2020-10-13 Nantkwest, Inc. Modified NK-92 haNK003 cells for the clinic
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
WO2019004550A1 (ko) 2017-06-26 2019-01-03 강원대학교 산학협력단 Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
JP2020528885A (ja) 2017-07-19 2020-10-01 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
US20200306302A1 (en) 2017-08-04 2020-10-01 Nantkwest, Inc. Treating and inhibiting leukemia with nk-92 cells
EP3664835B1 (en) 2017-08-09 2024-10-23 Juno Therapeutics, Inc. Methods and compositions for preparing genetically engineered cells
SG11202003501XA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
MX2021001254A (es) 2018-07-31 2021-05-12 Cullinan Mica Corp Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso.
US12516099B2 (en) 2018-08-09 2026-01-06 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
AU2019366960A1 (en) * 2018-10-23 2021-05-27 Regeneron Pharmaceuticals, Inc. Fc silenced antibody drug conjugates (ADCs) and uses thereof
EP4017876A4 (en) 2019-08-23 2023-09-06 Northwestern University MATERIALS AND METHODS FOR ACTIVATING ANTIGEN-SPECIFIC T CELL RESPONSES
US20250230246A1 (en) 2021-10-27 2025-07-17 Samyang Biopharm Usa Inc. Anti-mic antibodies with variant fc domains

Also Published As

Publication number Publication date
CN116249716A (zh) 2023-06-09
JP2023532852A (ja) 2023-08-01
TW202216776A (zh) 2022-05-01
US12139539B2 (en) 2024-11-12
KR20230012072A (ko) 2023-01-25
KR102594083B1 (ko) 2023-10-25
EP4178678A1 (en) 2023-05-17
KR20230152783A (ko) 2023-11-03
AU2021305084A1 (en) 2023-02-02
US20250026837A1 (en) 2025-01-23
WO2022010847A1 (en) 2022-01-13
CA3184940A1 (en) 2022-01-13
US20230235065A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
US11845801B2 (en) IL-15 prodrugs and methods of use thereof
AU2015374301B2 (en) Anti-CD47 antibodies and uses thereof
DK2595662T3 (en) Anti-CD19 antibody with ADCC and CDC functions and improved glycosylation profile
US20250026837A1 (en) MIC Antibodies and Binding Agents and Methods of Using the Same
US20170247463A1 (en) Modulating Agonistic TNFR Antibodies
AU2017228055A1 (en) Antibodies specific to human poliovirus receptor (PVR)
CA3192208A1 (en) Anti-par-2 antibodies and methods of use thereof
JP2025527535A (ja) 抗ｃｃｒ８抗体およびその使用
CA3255754A1 (en) Bispecific antibodies comprising an NRP1 binding domain and methods for using them
JP7854948B2 (ja) Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法
US20250230246A1 (en) Anti-mic antibodies with variant fc domains
JP2025538606A (ja) 抗ｃｃｒ８抗体及びその使用
CN117279954A (zh) 抗人cxcr5抗体及其用途
HK40087490A (zh) Mic抗体和结合剂及其使用方法
WO2023143478A1 (en) Novel anti-cd4 and anti-pd-l1 bispecific antibodies
CN114269780B (zh) 一种新型抗pd-l1抗体及其用途
TW202446419A (zh) 使用抗ｏｘ４０抗體與抗ｐｄ１抗體之組合的癌症治療方法
WO2025064951A1 (en) Anti-tumor antibodies
HK40104546A (zh) 抗人cxcr5抗体及其用途
EA046221B1 (ru) Cd33-связывающие полипептиды и их применение
EA039429B1 (ru) Способы лечения опухолей с применением биспецифического антитела cd3xcd20

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251104